^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Uveal Melanoma

Related cancers:
5d
PLEK2: a potential biomarker for metastasis and prognostic evaluation in uveal melanoma. (PubMed, Front Med (Lausanne))
PLEK2 is upregulated in UVM and correlates with poor patient prognosis, likely influencing the calcium signaling pathway. PLEK2 represents a promising prognostic biomarker and therapeutic target for UVM.
Journal
|
PLEK2 (Pleckstrin 2)
6d
MMP9 in pan-cancer and computational study to screen for MMP9 inhibitors. (PubMed, Am J Transl Res)
CHEMBL82047 and CHEMBL381163 are ideal compounds for inhibiting MMP9. The findings of this study will contribute to the design and improvement of MMP9-targeting drugs.
Journal • Tumor mutational burden • Pan tumor
|
TMB (Tumor Mutational Burden) • MMP9 (Matrix metallopeptidase 9)
|
MMP9 overexpression
9d
Metabolic inhibition induces pyroptosis in uveal melanoma. (PubMed, Mol Cancer Res)
Although the bispecific tebentafusp is FDA-approved, immunotherapy has largely failed, likely given the poorly immunogenic nature of UM...In particular, the CPT1 inhibitor, etomoxir, induced propidium iodide uptake, caspase 3 cleavage and the release of HMGB1 and IL-1β, indicating that the observed cleavage of gasdermins led to pyroptosis...Together, these data show that metabolic inhibitors can induce pyroptosis in UM cell lines, potentially offering an approach to enhance inflammation-mediated immune targeting in metastatic UM patients. Implications: Induction of pyroptosis by metabolic inhibition may alter the tumor immune microenvironment and improve the efficacy of immunotherapy in uveal melanoma.
Journal • IO biomarker
|
CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • IL1B (Interleukin 1, beta) • CPT1A (Carnitine Palmitoyltransferase 1A) • GSDME (Gasdermin E) • CASP1 (Caspase 1)
|
Kimmtrak (tebentafusp-tebn) • etomoxir (MIQ-001)
11d
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
P2, N=32, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Sep 2025
Trial completion date • Trial primary completion date • Metastases
|
Mektovi (binimetinib) • Beleodaq (belinostat)
13d
Psychoeducation for Uveal Melanoma (clinicaltrials.gov)
P=N/A, N=108, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
14d
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) (clinicaltrials.gov)
P2, N=51, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | Trial completion date: Sep 2028 --> Nov 2026 | Trial primary completion date: Jan 2027 --> May 2025
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
14d
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. (PubMed, Eur J Cancer)
Both treatment sequences are clinically feasible. A clinical benefit was noted in the sequential combination of ICIs followed by tebentafusp. This observation is limited by the retrospective nature of the study and merits further investigation in prospective clinical trials.
Journal • Checkpoint inhibition • IO biomarker • Metastases
|
GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
|
GNAQ mutation
|
Kimmtrak (tebentafusp-tebn)
18d
CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
P2, N=27, Active, not recruiting, Jose Lutzky, MD | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Jan 2024
Trial completion date • Trial primary completion date • Metastases
|
LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Opdivo (nivolumab) • relatlimab (BMS-986016)
18d
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma (clinicaltrials.gov)
P2, N=6, Active, not recruiting, Providence Health & Services | Recruiting --> Active, not recruiting | N=30 --> 6 | Trial primary completion date: Jun 2025 --> Dec 2024
Enrollment closed • Enrollment change • Trial primary completion date • Checkpoint inhibition • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
19d
New P2 trial • Metastases
|
roginolisib (IOA-244)
20d
Enrollment closed
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
melphalan
20d
Systematic drug screening and target analysis identify digitoxin as a potential therapy for uveal melanoma. (PubMed, Br J Pharmacol)
Given UVM's limited options, our study highlights the potential of digitoxin as a promising novel therapeutic agent for this aggressive and rare ocular cancer. Our comprehensive approach is effective in identifying the potent, cancer-specific therapeutic agents from herbal plants.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
21d
ATOM: Adjuvant Tebentafusp in High Risk Ocular Melanoma (clinicaltrials.gov)
P3, N=290, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting --> Recruiting
Enrollment open
|
Kimmtrak (tebentafusp-tebn)
24d
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
P1/2, N=253, Recruiting, Fusion Pharmaceuticals Inc. | Trial primary completion date: Jun 2024 --> Jun 2025
Trial primary completion date • Metastases
|
HER-2 negative
|
FPI-1434
28d
Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer. (PubMed, Exp Ther Med)
In conclusion, results from the present study suggest that ELF1 is overexpressed in GC. ELF1 combined with MMP9 can serve as a predictor of malignant biological behavior in GC and therefore a prognostic indicator for patients, due to its association with the tumor microenvironment.
Journal
|
KDR (Kinase insert domain receptor) • MLH1 (MutL homolog 1) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CDH1 (Cadherin 1) • CD4 (CD4 Molecule) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • MMP9 (Matrix metallopeptidase 9) • ELF1 (E74 Like ETS Transcription Factor 1) • PI3K (Phosphoinositide 3-kinases)
|
MMP9 overexpression
28d
Enrollment open • Combination therapy
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • melphalan
1m
Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma. (PubMed, J Immunother Cancer)
We also explore molecular and histological features of secondary resistance. Our case highlights that PD-1-resistant melanomas should be screened for GNAQ/11 mutations, as tebentafusp may be a treatment option in this extremely rare disease.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
GNAQ (G Protein Subunit Alpha Q) • PD-1 (Programmed cell death 1)
|
GNAQ mutation
|
Kimmtrak (tebentafusp-tebn)
1m
Gq/G11 oncogenic mutations promote PD-L1 expression and suppress tumor immunity. (PubMed, Eur J Cell Biol)
Furthermore, silencing YAP or treating with its inhibitor, Verteporfin, attenuated PD-L1 expression induced by Gq/G11 mutations, thereby enhancing T cell activation and T cell-mediated cytotoxicity. Collectively, this study reveals a potential role of Gq/G11 mutations on immune evasion of UM, a new mechanism of Gq/11 mutations-induced tumorigenesis, highlighting Gq/G11 and YAP as potential immunotherapeutic targets and suggesting Verteporfin as an adjuvant for immunotherapy of UM patients with GNAQ or GNA11 mutations.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
|
PD-L1 expression • GNAQ mutation • GNA11 mutation
|
Visudyne (verteporfin)
1m
The pan-cancer landscape of crosstalk between leukocyte transendothelial migration-related genes and tumor microenvironment relevant to prognosis and immunotherapy response. (PubMed, Transl Cancer Res)
Our results reveal that LTEMGs are closely associated with tumor microenvironment. Patients with high LTEMGs score might be resistant to immunotherapy.
Journal • IO biomarker • Pan tumor
|
KRAS (KRAS proto-oncogene GTPase)
1m
GNAQ/GNA11-Related Benign and Malignant Entities-A Common Histoembriologic Origin or a Tissue-Dependent Coincidence. (PubMed, Cancers (Basel))
Moreover, we discuss the role of SOX10-positive perivascular cells that may be implicated in the complex pathophysiology of GNAQ/GNA11-related entities. Understanding the common molecular foundation of these conditions opens new ways for research and treatment opportunities, potentially leading to more effective, personalized therapeutic strategies.
Review • Journal
|
GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11) • SOX10 (SRY-Box 10)
|
GNAQ mutation • GNA11 mutation • GNAQ mutation + GNA11 mutation
1m
MUM: Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (clinicaltrials.gov)
P1/2, N=341, Recruiting, IDEAYA Biosciences | Trial completion date: May 2025 --> Mar 2027 | Trial primary completion date: Oct 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
Xalkori (crizotinib) • Mektovi (binimetinib) • darovasertib (IDE196)
1m
Mutational Signature Comparison of Different Melanomas: Cutaneous versus Non-cutaneous (AMP 2024)
In summary, targeted sequencing of a large NGS panel can detect predicted ultraviolet radiation mutational signatures in skin cancer with >99% specificity. This preliminary result warrants a potential application of mutational signature characterization in routine tumor profiling testing. Further investigation with larger data sets will follow up to determine the overall sensitivity and specificity for detection.
TruSight Oncology 500 Assay
1m
Enrollment open • Combination therapy • Checkpoint inhibition • Metastases
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • RP2
2ms
SGSM2 in Uveal Melanoma: Implications for Survival, Immune Infiltration, and Drug Sensitivity. (PubMed, Protein Pept Lett)
SGSM2 may not only serve as an important indicator for prognostic assessment. Still, it may also be a key target for the development of new therapeutic approaches, providing new perspectives on the treatment of UVM patients.
Journal
|
MSI (Microsatellite instability)
|
GSK690693 • PHA 793887
2ms
Revealing the structural microenvironment of high metastatic risk uveal melanomas following decellularisation. (PubMed, Sci Rep)
Structural analyses of decellularised matrices revealed microarchitecture of differing fibre density and expression differences in collagen 4, collagen 6A1 and nidogen 1, between metastatic risk groups. This approach is a powerful tool for the generation of ECM matrices relevant to high metastatic risk UM.
Journal • Metastases
|
NID1 (Nidogen 1)
2ms
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=18, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases • Immune cell
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600 • CD123 expression
|
cyclophosphamide • fludarabine IV • MB-101
2ms
Treatment of Conjunctival Melanoma Cell Lines With a Light-Activated Virus-Like Drug Conjugate Induces Immunogenic Cell Death. (PubMed, Invest Ophthalmol Vis Sci)
The in vitro cytotoxicity was accompanied by exposure of DAMPs, suggesting Bel-sar is a potential treatment for CJM by a dual mechanism of action. This dual mechanism may provide a targeted and direct killing of tumor cells and induce an immune response which might decrease local recurrences and metastasis.
Preclinical • Journal
|
CALR (Calreticulin)
2ms
Enrollment closed • Combination therapy • Metastases
|
CD40 (CD40 Molecule)
|
Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
2ms
Deciphering the intricate relationship between macrophages, pigmentation, and prognosis in uveal melanoma. (PubMed, Lab Invest)
This could contribute to ineffective antitumor immune responses in UM patients. Our findings suggest avenues for developing novel therapeutic approaches to counteract these immunosuppressive effects in UM.
Journal
|
IL10 (Interleukin 10) • TYRP1 (Tyrosinase Related Protein 1) • DCT (Dopachrome Tautomerase) • MITF (Melanocyte Inducing Transcription Factor)
2ms
IGCMU: Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma (clinicaltrials.gov)
P=N/A, N=50, Recruiting, Centre Jean Perrin | Not yet recruiting --> Recruiting
Enrollment open
2ms
Machine learning and single-cell RNA sequencing reveal relationship between intratumor CD8+ T cells and uveal melanoma metastasis. (PubMed, Cancer Cell Int)
We developed a precise and stable 3-gene model to predict the metastatic risk and prognosis of patients. CD8 + T cells exhaustion in the tumor microenvironment play a crucial role in UM metastasis.
Journal • IO biomarker • Machine learning
|
CD8 (cluster of differentiation 8) • EDNRB (Endothelin Receptor Type B) • SLC25A3 (Solute Carrier Family 25 Member 3)
2ms
Delayed Distant Recurrence of a Uveal Melanoma 4 Decades after Enucleation. (PubMed, Case Rep Oncol)
The recurrence of a choroidal melanoma is substantiated by the histopathological and molecular analyses, including the finding of a GNA11 mutation. This case exemplifies a remarkably delayed distant recurrence of a choroidal melanoma, which manifested clinically 40 years following enucleation.
Journal • IO biomarker
|
BRAF (B-raf proto-oncogene) • GNA11 (G Protein Subunit Alpha 11) • MLANA (Melan-A)
|
BRAF mutation • GNA11 mutation
2ms
Enrollment change • Metastases
|
Amtagvi (lifileucel) • LN-145
2ms
PROQEM: Prospective Registration of Patient Data and Quality of Life in Eye Melanoma Patients (clinicaltrials.gov)
P=N/A, N=500, Recruiting, Leiden University Medical Center | N=250 --> 500
Enrollment change • HEOR
2ms
Expression of Markers Associated with Epithelial-Mesenchymal Transition and Extracellular Matrix Degradation in Human Uveal Melanoma. (PubMed, Bull Exp Biol Med)
The ratio of MMP-9 to TIMP-1 proteins related to the extracellular matrix degradation was higher in the tumor. These results may indicate activation of EMT-like process in the uveal melanoma cells and degradation of the extracellular matrix, which can contribute to the development of collective invasion in uveal melanoma.
Journal
|
CDH1 (Cadherin 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)
|
CDH1 expression • VIM expression
2ms
Neoadjuvant Tebentafusp for Uveal Melanoma (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Thomas Jefferson University | Trial completion date: Dec 2028 --> Apr 2029 | Initiation date: Sep 2024 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Oct 2025
Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
Kimmtrak (tebentafusp-tebn)
2ms
Azacytidine treatment affects the methylation pattern of genomic and cell-free DNA in uveal melanoma cell lines. (PubMed, BMC Cancer)
This data suggests that DNMT inhibitors cause changes in UM cells that are maintained in cfDNA. The results suggest that targeting methylation in UM treatment and monitoring response to treatment using cfDNA methylation could be a valuable tool.
Preclinical • Journal
|
BAP1 (BRCA1 Associated Protein 1)
|
azacitidine
2ms
NCI-2018-01211: Intravenous and Intrathecal Nivolumab in Treating Patients with Leptomeningeal Disease (clinicaltrials.gov)
P1, N=70, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | N=50 --> 70
Enrollment open • Enrollment change
|
BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
|
Opdivo (nivolumab)
2ms
Neuropeptide Precursor VGF Promotes Liver Metastatic Colonization of Gαq Mutant Uveal Melanoma by Facilitating Tumor Microenvironment via Paracrine Loops. (PubMed, Adv Sci (Weinh))
Furthermore, VGF directly binds to TGFBR2 and regulates TGF-β-SMAD signaling pathway, thereby regulating genes associated with endothelial-mesenchymal transition (EMT) to promote metastasis. Taken together, these findings identify VGF as a pivotal driver in the progression and metastasis of Gαq mutant UM and confers a promising therapeutic target and strategy for UM patients.
Journal • Metastases
|
TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)
2ms
Identification of targetable epigenetic vulnerabilities in uveal melanoma. (PubMed, bioRxiv)
RNA sequencing revealed a notable overlap between the genes and pathways affected by HDAC and BET inhibition, including the reversal of gene signatures linked to high metastatic risk and upregulation of genes associated with a neuronal phenotype. Together, we found that UM cells are particularly vulnerable to class I HDAC and BET inhibition, and highlight the BET inhibitor mivebresib as a promising candidate for further clinical evaluation.
Journal
|
BAP1 (BRCA1 Associated Protein 1)
|
BAP1 mutation
|
mivebresib (ABBV 075)
2ms
Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma. (PubMed, Cancers (Basel))
Additionally, apart from Tebentafusp, which is approved for the treatment of uveal melanoma, there is a lack of immunotherapies directly focused on melanoma cells...Obstacles preventing that progress include limited knowledge of CSPG4 function in human cancer and a lack of in vivo models that adequately represent patient immune responses and human melanoma biology. Despite several challenges, immunotherapy directed to CSPG4-expressing melanoma harbors significant potential to transform the treatment landscape.
Review • Journal • IO biomarker
|
CSPG4 (Chondroitin Sulfate Proteoglycan 4)
|
Kimmtrak (tebentafusp-tebn)
2ms
Gain of Chromosome 8q and High Expression of EZH2 May Predict Poor Prognosis in Chinese Patients with Uveal Melanoma. (PubMed, Asia Pac J Ophthalmol (Phila))
EZH2 and 8q gain could be taken into consideration when calculating poor prognosis in Chinese patients with uveal melanoma. Monosomy 3 showed no significance in distant metastasis, but this may be due to a small sample size.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)